Tina Albertson, MD, PhD - Lyell
bm-navigation: bm-t3-home-navigation
bm-pageheader: bm-t3-pageheader

Tina Albertson, MD, PhD

Chief Medical Officer and Head of Development

Tina Albertson, MD, PhD

Tina-AlbertsonDr. Albertson joins Lyell as Chief Medical Officer and Head of Development and brings over a decade of leadership in the clinical drug development of biologics and cellular therapies, from first-in-human to registrational clinical trials.

Most recently Dr. Albertson was VP of Global Drug Development at Juno Therapeutics, a BMS company, where she led a global team in the development of lisocabtagene maraleucel, a CD19-directed CAR T-cell product, from the first patient treated to BLA submission to the FDA for approval. In her five years at Juno, Dr. Albertson made significant contributions to the CAR T cell portfolio strategy and next-generation strategies to improve safety and efficacy through genetic engineering and combinations with other immunotherapies. She has a strong commitment to research and translational medicine in order to further innovation that leads to safer more effective cancer therapies and potentially cure patients with cancer.

Prior to joining Juno, Dr. Albertson was a medical director at Seattle Genetics in the experimental medicine group leading the early development of ADCs targeting CD70, CD30, and CD19 in solid tumor indications and hematologic malignancies.

Dr. Albertson spent nearly a decade in academic medicine in the department of Pediatric Hematology/Oncology at Seattle Children’s Hospital. Dr. Albertson cared for pediatric patients with cancer while performing laboratory research with a focus on DNA replication and repair. Her work in animal models investigated the role of mutation burden and tissue sensitivity to DNA damage on tumorigenesis and error catastrophe.

Dr. Albertson has her MD from Stanford University and her PhD in Cancer Biology from University of Washington.